Therapeutics News and Research

RSS

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

Whitehead researchers create 3D map to predict how genes are regulated in normal cells

Whitehead Institute researchers have created a map of the DNA loops that comprise the three dimensional (3D) structure of the human genome and regulate gene expression in human embryonic stem (ES) cells and adult cells. The location of genes and regulatory elements within this chromosomal framework could help scientists better navigate their genomic research, establishing relationships between mutations and disease development.

13 Dec 2015

ASU-led researchers add new worldwide resource to explore genes' deep and hidden messages

After a decade-long $3 billion international effort, scientists heralded the 2001 completion of the human genome as a moon landing achievement for biology and the key to finally solving intractable diseases like cancer.

12 Dec 2015

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

New biobank initiative may help unlock some of the mysteries linked to Down syndrome

Nationwide Children's Hospital and research advocacy group DownSyndrome Achieves have joined forces to create the first biobank in the country dedicated to collecting and managing blood samples from people with Down syndrome.

12 Dec 2015

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).

11 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Scientists looking at the antiviral mechanisms of two previously identified human monoclonal antibodies have found they potently inhibit chikungunya virus (CHIKV) at multiple stages of infection.

11 Dec 2015

Videregen-led TETRA consortium awarded EUR 6.8 million for pivotal Phase II trial of replacement trachea

The pan-European TETRA consortium, led by Videregen Limited, has been awarded EUR 6.8 million under the Horizon 2020 programme for a pivotal Phase II clinical trial of the company's tissue engineered replacement trachea.

10 Dec 2015

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit Therapeutics today announced that it has been awarded a 2.7 million dollar contract from the Defense Advanced Research Projects Agency to pursue optogenetic therapies for peripheral nervous system indications. The award, part of DARPA's Electrical Prescriptions (ElectRX) program, will enable Circuit to pursue research and development projects related to its treatment for neuropathic pain.

10 Dec 2015

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Flagship launches Rubius to develop functionalized red blood cells for treatment of serious diseases

Flagship Ventures, a leading innovation and venture firm focused on healthcare and sustainability, announced it has launched Rubius Therapeutics, to develop functionalized red blood cells for the treatment of autoimmune conditions, metabolic diseases, cancer, and other serious diseases.

9 Dec 2015

Gene may play role in protecting breast cancer patients from developing chemobrain

A team of researchers from the National University of Singapore has established that variation of a gene may have a role in protecting cancer patients from developing chemotherapy-induced cognitive impairment, commonly known as 'chemofog' or 'chemobrain'.

9 Dec 2015

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore.

9 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate.

2 Dec 2015

Medinol introduces NIRxcell CoCr Stent System to coronary marketplace

During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol Ltd. continued to introduce novel stent solutions to the coronary marketplace. During a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", a renowned physician panel discussed the key attributes of the currently available Medinol NIRxcell CoCr Coronary Stent System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved).

1 Dec 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

Therapeutics News and Research

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Whitehead researchers create 3D map to predict how genes are regulated in normal cells

ASU-led researchers add new worldwide resource to explore genes' deep and hidden messages

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

New biobank initiative may help unlock some of the mysteries linked to Down syndrome

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Videregen-led TETRA consortium awarded EUR 6.8 million for pivotal Phase II trial of replacement trachea

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Flagship launches Rubius to develop functionalized red blood cells for treatment of serious diseases

Gene may play role in protecting breast cancer patients from developing chemobrain

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Medinol introduces NIRxcell CoCr Stent System to coronary marketplace

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News